Defence Therapeutics (DE:DTC)
FRANKFURT:DTC
DTC Stock Chart & Stats
€0.52
>-€0.01(-0.20%)
At close: 4:00 PM EST
€0.52
>-€0.01(-0.20%)
Day’s Range― - ―
52-Week Range€0.26 - €0.59
Previous CloseN/A
Volume1.30K
Average Volume (3M)7.08K
Market Cap
€24.33M
Enterprise Value€31.89M
Total Cash (Recent Filing)€2.95M
Total Debt (Recent Filing)€1.56M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume10,650
30 Day Avg. Volume7,084
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology PlatformThe Accum® platform targets intracellular delivery and potency of biologics, creating a structural competitive advantage. A durable tech platform supports multiple programs, licensing or partner deals, and long-term value capture beyond any single clinical readout.
Diversified R&D PipelinePursuing oncology and infectious-disease programs plus ADC and immunotherapy approaches spreads scientific and execution risk. Multiple modality and indication exposure increases 'shots on goal' and makes long-term partnerships or selective asset licensing more feasible.
Balance Sheet Improvement (TTM)Positive TTM equity and rising total assets provide a tangible short-to-medium-term cushion versus prior negative equity, improving financial flexibility. This reduces immediate insolvency risk and gives time to progress programs or secure partnering/funding.
Bears Say
No Revenue; Recurring LossesThe firm remains development-stage with structurally no product revenue and sustained multi‑million dollar losses. Over the next several months this limits self-funding capacity, forces reliance on external capital, and heightens execution funding risk for programs.
Persistent Negative Cash FlowConsistent negative operating and free cash flow denotes ongoing cash burn that erodes runway. This structural cash deficit increases the probability of dilutive financings or deal-dependence, which can delay development timelines or alter program priorities.
Historical Equity Swings And Meaningful DebtPrior periods of negative equity plus non-trivial debt indicate volatile capitalization and financing strain. Such history raises dilution and leverage risk, which can constrain strategic optionality and negotiating power with partners or lenders over coming months.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was €0.26 and its highest was €0.59 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is €24.33M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 137 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.481%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---